AstraZeneca announces safety and effectiveness of phase 3 clinical trial of new crown vaccine

On March 25, local time, AstraZeneca's official website announced that the preliminary analysis results of the phase III clinical trial of the new crown vaccine AZD1222 were consistent with the interim analysis results announced on March 22.

The new crown vaccine AZD1222 was jointly invented by the University of Oxford and Vaccitech.

Clinical results show that the vaccine has an efficacy of 76% (CI: 68%-82%) in preventing symptomatic COVID-19; in addition, the results of all age groups are equivalent, and the efficacy of the vaccine for adults 65 years and older is 85% (CI : 58%-95%); the key secondary endpoints for the prevention of severe or critical illness and hospitalization confirmed 100% efficacy; these data further prove that the AstraZeneca vaccine is safe and effective.

This is the latest official data released after the safety of AZD1222 has been questioned by the US Data Security Monitoring Board (DSMB).

AstraZeneca said that the main analysis results of AZD1222 will be submitted in the next few weeks for peer review publication.

So far, the cumulative number of confirmed diagnoses in the world has exceeded 100 million.